Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ABBV-1162 · 1 trial · 1 indication
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Cmax of ABBV-1162
Beta of ABBV-1162
t1/2 of ABBV-1162
AUCt of ABBV-1162
AUCinf of ABBV-1162
| Arm | Type | Description |
|---|---|---|
| ABBV-1162 | EXPERIMENTAL | Participants will receive a single oral dose of ABBV-1162. |
| Placebo | PLACEBO_COMPARATOR | Participants will receive a single oral dose of placebo. |
| Name | Type | Description |
|---|---|---|
| ABBV-1162 | DRUG | Oral |
| Placebo | DRUG | Oral |
Inclusion Criteria: * Healthy individuals in general good health. * Blood pressure and heart rate measurements within specified ranges: systolic blood pressure \< 140 mmHg, diastolic blood pressure \< 90 mmHg, heart rate \<= 100 bpm and \>= 55 bpm, absence of orthostatic hypotension.
ABBV-1162 is an investigational small molecule drug being developed by AbbVie Inc. It is in Phase 1 clinical development, and the specific diseases or conditions it is intended to treat have not been disclosed. It is not yet approved for any use.
ABBV-1162 is being developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating the compound.
ABBV-1162 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA or any other regulatory agency. One Phase 1 trial has been registered to date, and it has not yet begun recruiting participants.
ABBV-1162 is being studied in one registered Phase 1 trial, NCT07832708, titled a study to assess adverse events and how oral ABBV-1162 moves through the body of healthy adults. The trial is not yet recruiting and is planned to enroll 40 healthy volunteers aged 18 years and older.
Yes. The Phase 1 trial of ABBV-1162, NCT07832708, is randomized, double blind, and placebo controlled. It is designed to assess adverse events and how the oral drug moves through the body, and it plans to enroll 40 healthy adult volunteers.